CA2096962A1 - Composition contenant des antagonistes du recepteur h2 de l'histamine et materiau bioadhesif - Google Patents

Composition contenant des antagonistes du recepteur h2 de l'histamine et materiau bioadhesif

Info

Publication number: CA2096962A1
Authority: CA; Canada
Prior art keywords: histamine; receptor antagonist; treatment; cimetidine; gastric
Prior art date: 1990-11-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002096962A

Other languages

English (en)

Inventor

Adrian Francis Davis

Mark Coke

John Edward O'mullane

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Beecham Group PLC

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-11-27

Filing date

1991-11-21

Publication date

1992-05-28

1991-11-21 Application filed by Individual filed Critical Individual

1992-05-28 Publication of CA2096962A1 publication Critical patent/CA2096962A1/fr

Status Abandoned legal-status Critical Current

Links

239000000227 bioadhesive Substances 0.000 title claims abstract description 27
239000000463 material Substances 0.000 title claims abstract description 23
239000000203 mixture Substances 0.000 title claims description 36
229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 title description 6
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 title 1
230000001387 anti-histamine Effects 0.000 title 1
239000000739 antihistaminic agent Substances 0.000 title 1
239000003485 histamine H2 receptor antagonist Substances 0.000 claims abstract description 58
229940122957 Histamine H2 receptor antagonist Drugs 0.000 claims abstract description 54
238000011282 treatment Methods 0.000 claims abstract description 27
208000012895 Gastric disease Diseases 0.000 claims abstract description 16
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
229960001380 cimetidine Drugs 0.000 claims description 30
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical group N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 30
229940069428 antacid Drugs 0.000 claims description 22
239000003159 antacid agent Substances 0.000 claims description 22
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 18
230000002496 gastric effect Effects 0.000 claims description 16
230000001458 anti-acid effect Effects 0.000 claims description 15
230000003139 buffering effect Effects 0.000 claims description 14
210000002784 stomach Anatomy 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 13
210000001711 oxyntic cell Anatomy 0.000 claims description 13
102000005962 receptors Human genes 0.000 claims description 9
108020003175 receptors Proteins 0.000 claims description 9
239000002253 acid Substances 0.000 claims description 8
239000011872 intimate mixture Substances 0.000 claims description 7
230000001154 acute effect Effects 0.000 claims description 6
238000002560 therapeutic procedure Methods 0.000 claims description 6
230000003472 neutralizing effect Effects 0.000 claims description 5
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
208000025865 Ulcer Diseases 0.000 claims description 4
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 4
229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 4
239000002552 dosage form Substances 0.000 claims description 4
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 4
239000000347 magnesium hydroxide Substances 0.000 claims description 4
229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 4
238000000034 method Methods 0.000 claims description 4
229960000620 ranitidine Drugs 0.000 claims description 4
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 4
-1 alkali metal salts Chemical class 0.000 claims description 3
229960001596 famotidine Drugs 0.000 claims description 3
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 3
231100000397 ulcer Toxicity 0.000 claims description 3
PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical class NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 claims description 2
239000005995 Aluminium silicate Substances 0.000 claims description 2
239000005711 Benzoic acid Chemical class 0.000 claims description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
229910052783 alkali metal Inorganic materials 0.000 claims description 2
229910000147 aluminium phosphate Chemical class 0.000 claims description 2
229910000323 aluminium silicate Inorganic materials 0.000 claims description 2
PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 claims description 2
235000012211 aluminium silicate Nutrition 0.000 claims description 2
FIUBOPPLFYFRMW-UHFFFAOYSA-E aluminum;trimagnesium;carbonate;heptahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Al+3].[O-]C([O-])=O FIUBOPPLFYFRMW-UHFFFAOYSA-E 0.000 claims description 2
235000010233 benzoic acid Nutrition 0.000 claims description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
229940036348 bismuth carbonate Drugs 0.000 claims description 2
229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 2
GMZOPRQQINFLPQ-UHFFFAOYSA-H dibismuth;tricarbonate Chemical compound [Bi+3].[Bi+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O GMZOPRQQINFLPQ-UHFFFAOYSA-H 0.000 claims description 2
GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 claims description 2
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical class C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
239000000499 gel Substances 0.000 claims description 2
229910052749 magnesium Inorganic materials 0.000 claims description 2
239000011777 magnesium Substances 0.000 claims description 2
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
239000001095 magnesium carbonate Substances 0.000 claims description 2
229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
239000000395 magnesium oxide Substances 0.000 claims description 2
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
239000000391 magnesium silicate Substances 0.000 claims description 2
229940099273 magnesium trisilicate Drugs 0.000 claims description 2
229910000386 magnesium trisilicate Inorganic materials 0.000 claims description 2
235000019793 magnesium trisilicate Nutrition 0.000 claims description 2
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
235000011007 phosphoric acid Nutrition 0.000 claims description 2
239000004334 sorbic acid Chemical class 0.000 claims description 2
235000010199 sorbic acid Nutrition 0.000 claims description 2
229940075582 sorbic acid Drugs 0.000 claims description 2
230000008685 targeting Effects 0.000 claims description 2
239000011975 tartaric acid Chemical class 0.000 claims description 2
235000002906 tartaric acid Nutrition 0.000 claims description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
235000010216 calcium carbonate Nutrition 0.000 claims 1
238000011065 in-situ storage Methods 0.000 claims 1
235000014380 magnesium carbonate Nutrition 0.000 claims 1
235000012245 magnesium oxide Nutrition 0.000 claims 1
MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 28
229960004291 sucralfate Drugs 0.000 description 28
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
239000000523 sample Substances 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
102000003710 Histamine H2 Receptors Human genes 0.000 description 7
108090000050 Histamine H2 Receptors Proteins 0.000 description 7
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
239000000243 solution Substances 0.000 description 6
208000008469 Peptic Ulcer Diseases 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
230000009467 reduction Effects 0.000 description 5
239000000725 suspension Substances 0.000 description 5
230000009858 acid secretion Effects 0.000 description 4
230000009471 action Effects 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
239000006172 buffering agent Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000012377 drug delivery Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
208000007882 Gastritis Diseases 0.000 description 3
206010020601 Hyperchlorhydria Diseases 0.000 description 3
208000007107 Stomach Ulcer Diseases 0.000 description 3
201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 3
239000000556 agonist Substances 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
201000000052 gastrinoma Diseases 0.000 description 3
229960001340 histamine Drugs 0.000 description 3
238000007391 self-medication Methods 0.000 description 3
208000028399 Critical Illness Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
230000000767 anti-ulcer Effects 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
239000000599 controlled substance Substances 0.000 description 2
230000001120 cytoprotective effect Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
201000006549 dyspepsia Diseases 0.000 description 2
230000029142 excretion Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
201000005917 gastric ulcer Diseases 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
208000011906 peptic ulcer disease Diseases 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
229920002994 synthetic fiber Polymers 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
VQJMAIZOEPPELO-KYGIZGOZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-(2-hydroxy-5-methylhexan-2-yl)-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol hydrochloride Chemical compound Cl.CO[C@]12CC[C@@]3(C[C@@H]1C(C)(O)CCC(C)C)[C@H]1Cc4ccc(O)c5O[C@@H]2[C@]3(CCN1CC1CC1)c45 VQJMAIZOEPPELO-KYGIZGOZSA-N 0.000 description 1
JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
WYUYEJNGHIOFOC-VVTVMFAVSA-N 2-[(z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C\CN1CCCC1 WYUYEJNGHIOFOC-VVTVMFAVSA-N 0.000 description 1
229920002126 Acrylic acid copolymer Polymers 0.000 description 1
241000331231 Amorphocerini gen. n. 1 DAD-2008 Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
241000723438 Cercidiphyllum japonicum Species 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
101150056637 Hrh2 gene Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
208000004221 Multiple Trauma Diseases 0.000 description 1
229920000148 Polycarbophil calcium Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000001164 aluminium sulphate Substances 0.000 description 1
235000011128 aluminium sulphate Nutrition 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
BUACSMWVFUNQET-UHFFFAOYSA-H dialuminum;trisulfate;hydrate Chemical compound O.[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O BUACSMWVFUNQET-UHFFFAOYSA-H 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229920001002 functional polymer Polymers 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
208000024798 heartburn Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
235000019629 palatability Nutrition 0.000 description 1
230000001175 peptic effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000000419 plant extract Substances 0.000 description 1
229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
229950005134 polycarbophil Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229940126409 proton pump inhibitor Drugs 0.000 description 1
239000000612 proton pump inhibitor Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biophysics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

CA002096962A 1990-11-27 1991-11-21 Composition contenant des antagonistes du recepteur h2 de l'histamine et materiau bioadhesif Abandoned CA2096962A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB9025710.6		1990-11-27
GB909025710A GB9025710D0 (en)	1990-11-27	1990-11-27	Novel treatment

Publications (1)

Publication Number	Publication Date
CA2096962A1 true CA2096962A1 (fr)	1992-05-28

Family

ID=10686017

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002096962A Abandoned CA2096962A1 (fr)	1990-11-27	1991-11-21	Composition contenant des antagonistes du recepteur h2 de l'histamine et materiau bioadhesif

Country Status (9)

Country	Link
EP (1)	EP0559812A1 (fr)
JP (1)	JPH06502855A (fr)
AU (1)	AU659422B2 (fr)
CA (1)	CA2096962A1 (fr)
GB (1)	GB9025710D0 (fr)
IE (1)	IE914091A1 (fr)
PL (1)	PL168421B1 (fr)
WO (1)	WO1992009286A1 (fr)
ZA (1)	ZA919290B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4139883A1 (de) *	1991-11-29	1993-06-03	Michael Prof Dr Dittgen	Verfahren zur herstellung bioadhaesiver arzneimittel
AU7322394A (en) *	1993-07-06	1995-02-06	Mcneil-Ppc, Inc.	H2 antagonist-sucralfate-antiflatulent combinations
WO1995010274A1 (fr) *	1993-10-14	1995-04-20	F.H. Faulding & Co. Limited	Composition pharmaceutique aqueuse
GB9407235D0 (en) *	1994-04-12	1994-06-08	Glaxo Group Ltd	Pharmaceutical compositions
US5593696A (en) *	1994-11-21	1997-01-14	Mcneil-Ppc, Inc.	Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
WO1996031218A1 (fr) *	1995-04-03	1996-10-10	Chugai Seiyaku Kabushiki Kaisha	Composition pharmaceutique contenant du sucralfate
WO1997028823A1 (fr) *	1996-02-08	1997-08-14	Chugai Seiyaku Kabushiki Kaisha	Procede d'utilisation d'un agent antiacide et preparation pharmaceutique le contenant
EP1074259A4 (fr) *	1998-04-01	2001-06-27	Chugai Pharmaceutical Co Ltd	Medicaments preventifs des gastrites alcooliques
US6319513B1 (en)	1998-08-24	2001-11-20	The Procter & Gamble Company	Oral liquid mucoadhesive compounds
EP4522122A1 (fr) *	2022-05-09	2025-03-19	SYRI Research Private Limited	Formulation orale liquide de famotidine ou d'un sel pharmaceutiquement acceptable de celle-ci

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3710462A1 (de) *	1987-03-30	1988-10-13	Heumann Pharma Gmbh & Co	Pharmazeutische zubereitung zur behandlung von erkrankungen des magen-darm-traktes
US4975281A (en) *	1989-01-30	1990-12-04	E. R. Squibb & Sons, Inc.	Anti-ulcer composition
EP0403048A3 (fr) *	1989-06-14	1991-01-30	Warner-Lambert Company	Un modèle de structure de système craniomandibulaire humain

1990
- 1990-11-27 GB GB909025710A patent/GB9025710D0/en active Pending
1991
- 1991-11-21 EP EP92902524A patent/EP0559812A1/fr not_active Withdrawn
- 1991-11-21 AU AU89098/91A patent/AU659422B2/en not_active Ceased
- 1991-11-21 WO PCT/GB1991/002063 patent/WO1992009286A1/fr not_active Ceased
- 1991-11-21 PL PL91299319A patent/PL168421B1/pl unknown
- 1991-11-21 CA CA002096962A patent/CA2096962A1/fr not_active Abandoned
- 1991-11-21 JP JP4500445A patent/JPH06502855A/ja active Pending
- 1991-11-25 ZA ZA919290A patent/ZA919290B/xx unknown
- 1991-11-25 IE IE409191A patent/IE914091A1/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP0559812A1 (fr)	1993-09-15
AU659422B2 (en)	1995-05-18
ZA919290B (en)	1992-09-30
JPH06502855A (ja)	1994-03-31
PL168421B1 (en)	1996-02-29
IE914091A1 (en)	1992-06-03
GB9025710D0 (en)	1991-01-09
AU8909891A (en)	1992-06-25
WO1992009286A1 (fr)	1992-06-11

Publication	Publication Date	Title
US5629026A (en)	1997-05-13	Compositions containing histamine-H2-receptor antagonists at low dosage
AU752214B2 (en)	2002-09-12	Flash-melt oral dose formulations
US5275823A (en)	1994-01-04	Pharmaceutical compositions
CA2074215C (fr)	2001-12-18	Formulations orales ameliorees de nucleosides a base de dideoxypurine
AU620866B2 (en)	1992-02-27	Pharmaceutical compositions
JPH05112445A (ja)	1993-05-07	作用開始を速くし潜在特性を増加させる移送システム
NZ233441A (en)	1992-03-26	Medicament tablet containing a chewable base and an effervescent couple
HK1004522B (en)	1998-11-27	Pharmaceutical formulation
BG65502B1 (bg)	2008-10-31	Фармацевтичен състав за лечение на остри неразположения и неговото използване
CZ314899A3 (cs)	2000-03-15	Farmaceutický prostředek
AU659422B2 (en)	1995-05-18	Composition containing antihistamine H2 receptor antagonists and bioadhesive material
EP0533770A1 (fr)	1993-03-31	Nouveau traitement
AU4082793A (en)	1993-12-30	Compositions based on histamine h2-receptor antagonists and cationic exchangers complexes
EP1807068B1 (fr)	2010-03-17	Préparation incluant de l acétaminophène, de la caféine et de l aspirine avec un agent alcalin pour en faciliter l absorption
WO1996008238A1 (fr)	1996-03-21	Utilisation d'agents d'accroissement paracellulaires tels que le glucose pour accroitre l'absorption d'antagonistes du recepteur h2 de l'histamine
CN1140996A (zh)	1997-01-22	雷尼替丁和碳酸钙药物复合品

Legal Events

Date	Code	Title	Description
1998-11-23	FZDE	Dead